WAM
NYMX

Weiss Asset Management’s Nymox Pharmaceutical Corp NYMX Stock Holding History

Weiss Asset Management’s Portfolio NYMX Stock Details NYMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-49,700
Closed -$72K – 450
2019
Q2 		$72K Buy
+49,700
New +$87K ﹤0.01% 311

Other funds holding NYMX

FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
WB
Webster Bank Waterbury, Connecticut $1.15B AUM 23.08% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Weiss Asset Management's NYMX Position: Q3 2019 in Review

Weiss Asset Management sold out of Nymox Pharmaceutical Corp (NYMX) in Q3 2019, closing a stake of 49,700 shares — an estimated $72K sold.

Weiss Asset Management first reported a position in NYMX in Q2 2019 and held it in 1 quarter. The position peaked at $72K in Q2 2019. 38 funds tracked by Wall St. Rank hold NYMX as of Q3 2019.

  • Weiss Asset Management reported no remaining Nymox Pharmaceutical Corp position as of Q3 2019 after selling out during the quarter.
  • Weiss Asset Management sold 49,700 Nymox Pharmaceutical Corp shares in Q3 2019, an estimated $72K.
  • Weiss Asset Management first reported a position in Nymox Pharmaceutical Corp in Q2 2019 and held it in 1 quarter.
  • Weiss Asset Management's Nymox Pharmaceutical Corp position peaked at $72K in Q2 2019.
  • 38 funds tracked by Wall St. Rank held Nymox Pharmaceutical Corp as of Q3 2019.

Based on Weiss Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.